

Bone Therapeutics to Present at Upcoming Investor Conferences

Gosselies, Belgium, 8 April 2013 - BONE THERAPEUTICS, the leading international biopharmaceutical company focused on innovative cell therapy products for the treatment of bone diseases, announces that Dr Enrico Bastianelli, Chief Executive Officer of Bone Therapeutics, will present at the following upcoming investor conferences:

[BioCapital Europe 2013](#), taking place on Wednesday 17th April at Sofitel Amsterdam The Grand, Amsterdam. Enrico Bastianelli will be presenting at 4.20pm in session Room 3.

[BioTrinity 2013](#), taking place from Tuesday 14th May to Thursday 16th May at Newbury Racecourse, Newbury, UK. Enrico Bastianelli will be presenting on Wednesday 15th May in the Company Showcase session from 3.30pm to 4.30pm.

[BioEquity Europe](#), taking place from Wednesday 22nd May to Thursday 23rd May at the Sheraton Stockholm, Sweden.

[EPIC Biotechnology conference](#), taking place on Thursday 6th June at The King's Fund in London, UK. Enrico Bastianelli will be presenting at 4.00pm in the Clinical Trials session.

If you would like to arrange a meeting with Dr Bastianelli, please request a meeting via the conference of interest partnering system by registering. Alternatively, you can request a meeting by visiting the upcoming events page on Bone Therapeutics website www.bonetherapeutics.com.

Follow us :   

About Bone Therapeutics

Bone Therapeutics is a leading international biopharmaceutical company focused on innovative cell therapy products for the treatment of bone diseases. Utilizing the Company's unique knowledge of the bone/joint physiology and long-standing expertise in cell therapy and cell transplantation, Bone Therapeutics has created a fully integrated business with an advanced product pipeline comprising novel bone cell products, tailored in-house production methods, and minimally invasive treatment techniques.

Bone Therapeutics' lead product, PREOB®, is an autologous bone cell product, currently in Phase III clinical trials for the treatment of osteonecrosis and non-union fractures. Bone Therapeutics is also developing an allogeneic bone cell therapy product, ALLOB®, which is expected to enter the clinic in 2013, and MXB, a combined cell-matrix product for the treatment of large bone defects, currently in preclinical development. All of Bone Therapeutics' cell therapy products are manufactured to the highest GMP standards and protected by a rich IP estate.

The bone disease and reconstruction market is one of the largest healthcare markets in the world, with more than 4 million procedures requiring bone grafts performed annually in Europe and the USA alone. Bone Therapeutics is operating in areas where demand for new products is high and competition is low. Founded in 2006, Bone Therapeutics is privately held and headquartered in Gosselies (south of Brussels), Belgium. Further information is available at: bonetherapeutics.com

For further information, please contact:

Bone Therapeutics SA
Tel: +32 (0)2 529 59 90
Enrico Bastianelli, Chief Executive Officer
info@bonetherapeutics.com

M:Communications
Mary-Jane Elliott, Amber Bielecka, Hollie Vile
Tel: +44 (0) 20 7920 2333
bonetherapeutics@mcomgroup.com